Price
$9.05
Decreased by -2.90%
Dollar Volume
28.95 M
ADR%
6.8
Earnings Report Date (estimate)
Feb 27, 23 (-0.28)
Market Cap.
1.29 B
Shares Float
130.59 M
Shares Outstanding
142.11 M
Beta
0.84
Price / Earnings
-7.15
BPR
40.20
20D Range
7.03 9.70
50D Range
4.07 9.70
200D Range
4.07 13.41
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -0.06
Increased by +84.62%
-0.17
Increased by +64.71%
Aug 4, 22 -0.25
Increased by +32.43%
-0.22
Decreased by -13.64%
May 10, 22 -0.27
Increased by +32.50%
-0.27
Feb 28, 22 -0.25
Decreased by -400.00%
-0.27
Increased by +7.41%
Nov 3, 21 -0.39
Decreased by -39.29%
-0.33
Decreased by -18.18%
Aug 5, 21 -0.37
Decreased by -42.31%
-0.36
Decreased by -2.78%
May 6, 21 -0.40
Decreased by -166.67%
-0.36
Decreased by -11.11%
Feb 24, 21 -0.05
Increased by +93.59%
-0.24
Increased by +79.17%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 55.78 M
Increased by +280.30%
-8.99 M
Increased by +82.11%
Decreased by -16.12%
Increased by +95.30%
Jun 30, 22 28.19 M
Increased by +325.85%
-35.52 M
Increased by +24.45%
Decreased by -125.98%
Increased by +82.26%
Mar 31, 22 21.63 M
Increased by +2.27 K%
-37.63 M
Increased by +25.31%
Decreased by -174.01%
Increased by +96.84%
Dec 31, 21 23.40 M
Decreased by -53.22%
-33.32 M
Decreased by -47.73%
Decreased by -142.38%
Decreased by -215.80%
Sep 30, 21 14.67 M
Increased by +50.48 K%
-50.26 M
Decreased by -47.53%
Decreased by -342.64%
Increased by +99.71%
Jun 30, 21 6.62 M
Increased by +22.73 K%
-47.01 M
Decreased by -59.22%
Decreased by -710.12%
Increased by +99.30%
Mar 31, 21 914.00 K
Increased by +2.95 K%
-50.38 M
Decreased by -204.70%
Decreased by -5.51 K%
Increased by +90.00%
Dec 31, 20 50.03 M
Increased by +172.42 K%
-22.56 M
Increased by +70.51%
Decreased by -45.08%
Increased by +99.98%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.